Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study

Jingwen Ai, Jitao Wang, Dengxiang Liu, Huiling Xiang, Ying Guo, Jiaojian Lv, Qiran Zhang, Jinlong Li, Xiaochong Zhang, Qianqian Li, Jing Liang, Xiaoqing Guo, Yinong Feng, Luxiang Liu, Xuying Zhang, Wei Qin, Xiaodong Wang, Wei Rao, Qun Zhang, Qiuju Tian, Yanliang Zhang, Faren Xie, Shujun Jiang, Yan Yan, Yuanwang Qiu, Hangyuan Wu, Zhiyun Hou, Nina Zhang, Aiguo Zhang, Jiansong Ji, Jie Yang, Jiansheng Huang, Zhongwei Zhao, Ye Gu, Li Bian, Zhen Zhang, Shengqiang Zou, Hailei Ji, Guohong Ge, Xiufang Du, Aifang Hou, Ying Zhu, Qingwei Cong, Juan Xu, Hongmei Zu, Yun Wang, Zhaolan Yan, Xiaosong Yan, Yangzhen BianBa, Qu Ci, Liting Zhang, Shiying Yang, Xiaoqin Gao, Li Zhong, Song He, Chuan Liu, Yifei Huang, Yanna Liu, Dan Xu, Qingliang Zhu, Xinxin Xu, Muhan Lv, Wenhong Zhang, Xiaolong Qi, Jingwen Ai, Jitao Wang, Dengxiang Liu, Huiling Xiang, Ying Guo, Jiaojian Lv, Qiran Zhang, Jinlong Li, Xiaochong Zhang, Qianqian Li, Jing Liang, Xiaoqing Guo, Yinong Feng, Luxiang Liu, Xuying Zhang, Wei Qin, Xiaodong Wang, Wei Rao, Qun Zhang, Qiuju Tian, Yanliang Zhang, Faren Xie, Shujun Jiang, Yan Yan, Yuanwang Qiu, Hangyuan Wu, Zhiyun Hou, Nina Zhang, Aiguo Zhang, Jiansong Ji, Jie Yang, Jiansheng Huang, Zhongwei Zhao, Ye Gu, Li Bian, Zhen Zhang, Shengqiang Zou, Hailei Ji, Guohong Ge, Xiufang Du, Aifang Hou, Ying Zhu, Qingwei Cong, Juan Xu, Hongmei Zu, Yun Wang, Zhaolan Yan, Xiaosong Yan, Yangzhen BianBa, Qu Ci, Liting Zhang, Shiying Yang, Xiaoqin Gao, Li Zhong, Song He, Chuan Liu, Yifei Huang, Yanna Liu, Dan Xu, Qingliang Zhu, Xinxin Xu, Muhan Lv, Wenhong Zhang, Xiaolong Qi

Abstract

Background & aims: We aimed to assess the safety and immunogenicity of inactivated whole-virion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic liver diseases (CLD) in this study.

Methods: This was a prospective, multi-center, open-label study. Participants aged over 18 years with confirmed CLD and healthy volunteers were enrolled. All participants received 2 doses of inactivated whole-virion SARS-CoV-2 vaccines. Adverse reactions were recorded within 14 days after any dose of SARS-CoV-2 vaccine, laboratory testing results were collected after the second dose, and serum samples of enrolled subjects were collected and tested for SARS-CoV-2 neutralizing antibodies at least 14 days after the second dose.

Results: A total of 581 participants (437 patients with CLD and 144 healthy volunteers) were enrolled from 15 sites in China. Most adverse reactions were mild and transient, and injection site pain (n = 36; 8.2%) was the most frequently reported adverse event. Three participants had grade 3 aminopherase elevation (defined as alanine aminopherase >5 upper limits of normal) after the second dose of inactivated whole-virion SARS-CoV-2 vaccination, and only 1 of them was judged as severe adverse event potentially related to SARS-CoV-2 vaccination. The positive rates of SARS-CoV-2 neutralizing antibodies were 76.8% in the noncirrhotic CLD group, 78.9% in the compensated cirrhotic group, 76.7% in the decompensated cirrhotic group (P = .894 among CLD subgroups), and 90.3% in healthy controls (P = .008 vs CLD group).

Conclusion: Inactivated whole-virion SARS-CoV-2 vaccines are safe in patients with CLD. Patients with CLD had lower immunologic response to SARS-CoV-2 vaccines than healthy population. The immunogenicity is similarly low in noncirrhotic CLD, compensated cirrhosis, and decompensated cirrhosis.

Keywords: Chronic Liver Diseases; Cirrhosis; Immunogenicity; SARS-CoV-2 Vaccines; Safety.

Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Serological antibody response of SARS-CoV-2 vaccines in patients with chronic liver diseases. Positive rates and concentrations of neutralizing antibodies to SARS-CoV-2 induced after the whole schedule of SARS-CoV-2 vaccination in participants with noncirrhotic CLD, compensated cirrhosis, decompensated cirrhosis, and healthy controls. Concentrations over 10.0 AU/mL were considered as positive, and concentrations below 10.0 AU/mL as negative. NS, Non-significant. ∗P value < .05; ∗∗P value < .01.

References

    1. World Health Organiztion coronavirus (COVID-19) dashboard. Available at: . Accessed October 1, 2021.
    1. Carvalho T., Krammer F., Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021;21:245–256.
    1. Younossi Z., Anstee Q.M., Marietti M., et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
    1. Asrani S.K., Devarbhavi H., Eaton J., et al. Burden of liver diseases in the world. J Hepatol. 2019;70:151–171.
    1. World Health Organization hepatitis topics. Available at:
    1. Paik J.M., Golabi P., Younossi Y., et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72:1605–1616.
    1. Marjot T., Moon A.M., Cook J.A., et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567–577.
    1. Sarin S.K., Choudhury A., Lau G.K., et al. APASL COVID Task Force APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection: the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) Hepatol Int. 2020;14:690–700.
    1. Iavarone M., D’Ambrosio R., Soria A., et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73:1063–1071.
    1. Xia S., Zhang Y., Wang Y., et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51.
    1. Zhang Y., Zeng G., Pan H., et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–192.
    1. Ramasamy M.N., Minassian A.M., Ewer K.J., et al. Oxford COVID Vaccine Trial Group Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–1993.
    1. Walsh E.E., Frenck R.W., Jr., Falsey A.R., et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450.
    1. Zhu F.C., Li Y.H., Guan X.H., et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854.
    1. Boyarsky B.J., Werbel W.A., Avery R.K., et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325:1784–1786.
    1. Zitt E., Davidovic T., Schimpf J., et al. The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 vaccine in hemodialysis patients. Front Immunol. 2021;12:704773.
    1. Rabinowich L., Grupper A., Baruch R., et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021;75:435–438.
    1. Wang J., Hou Z., Liu J., et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol. 2021;75:439–441.
    1. Thuluvath P.J., Robarts P., Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol. 2021;75:1434–1439.
    1. National Health Commission of the People's Republic of China Guidance of SARS-CoV-2 vaccination (First version) Chinese J Clin Infect Dis. 2021;14:89–90.
    1. Aggeletopoulou I., Davoulou P., Konstantakis C., et al. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol. 2017;27
    1. Keeffe E.B., Iwarson S., McMahon B.J., et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27:881–886.
    1. Albillos A., Lario M., Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–1396.
    1. Dhanda A.D., Collins P.L. Immune dysfunction in acute alcoholic hepatitis. World J Gastroenterol. 2015;21:11904–11913.
    1. Zhou L., He R., Fang P., et al. Hepatitis B virus rigs the cellular metabolome to avoid innate immune recognition. Nat Commun. 2021;12:98.
    1. Gao B., Jeong W.I., Tian Z. Liver: An organ with predominant innate immunity. Hepatology. 2008;47:729–736.
    1. Schirren C.A., Jung M.C., Zachoval R., et al. Analysis of T cell activation pathways in patients with liver cirrhosis, impaired delayed hypersensitivity and other T cell-dependent functions. Clin Exp Immunol. 1997;108:144–150.
    1. Wiedermann U., Garner-Spitzer E., Wagner A. Primary vaccine failure to routine vaccines: why and what to do? Hum Vaccin Immunother. 2016;12:239–243.
    1. Yang S., Tian G., Cui Y., et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016;6:27251.
    1. Fischinger S., Boudreau C.M., Butler A.L., et al. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41:239–249.
    1. Fehervari Z. Vaccine sex differences. Nat Immunol. 2019;20:111.
    1. Furman D., Hejblum B.P., Simon N., et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A. 2014;111:869–874.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner